NCT07561814

Brief Summary

The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress. The main questions it aims to answer are:

  • Can combining these types of data more accurately estimate how long a person might survive?
  • Can it better predict the risk of the cancer coming back? Participants will not have any extra tests or treatments. They will:
  • Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)
  • Receive a follow-up phone call about every 3 months for up to 3 years to share health updates

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,030

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Dec 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Dec 2025Dec 2029

Study Start

First participant enrolled

December 8, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

April 25, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 1, 2026

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2029

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

3.6 years

First QC Date

April 25, 2026

Last Update Submit

April 25, 2026

Conditions

Pancreatic Cancer

Keywords

Pancreatic cancerMultimodal dataDeep learningPredictive modelPrognosisCT imaging

Outcome Measures

Primary Outcomes (3)

  • overall survival

    3 years

  • recurrence free survival

    3 years

  • recurrence status within one year after surgery

    3 years

Study Arms (2)

Retrospective cohort

prospective cohort

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will be drawn from patients receiving surgical treatment for pancreatic cancer at two academic medical centers in China: the Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University (Shanghai) and the Third Xiangya Hospital, Central South University (Changsha). The retrospective cohort includes patients diagnosed between January 2023 and December 2025, identified from hospital electronic health records. The prospective cohort will comprise newly diagnosed patients enrolled consecutively. Both cohorts originate from the same clinical settings, representing a tertiary hospital-based population with consistent diagnostic and treatment standards.

You may qualify if:

  • Age ≥ 18 years.
  • Histologically or cytologically confirmed diagnosis of pancreatic cancer.
  • Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
  • Underwent surgical treatment for pancreatic cancer at a participating center of this study.

You may not qualify if:

  • Age \< 18 years (minors).
  • Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
  • patients unable to comply with follow-up or provide informed consent.
  • Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2026

First Posted

May 1, 2026

Study Start

December 8, 2025

Primary Completion (Estimated)

July 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

May 1, 2026

Record last verified: 2026-04

Locations

CN(1)